Organization
Swedish Medical Center/Providence St. Joseph Health and University of Washington, Rheumatology, Seattle, United States of America
4 abstracts
Abstract
A RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING SECUKINUMAB 300 MG AND 150 MG AT WEEK 52 IN PATIENTS WITH ANKYLOSING SPONDYLITIS WHO DID NOT ACHIEVE INACTIVE DISEASE DURING AN INITIAL 16 WEEKS OF OPEN-LABEL TREATMENT WITH SECUKINUMAB 150 MGOrg: Oregon Health & Science University, Rheumatology, Portland, United States of America, Altoona Center for Clinical Research, Altoona Arthritis and Osteoporosis Center, Duncansville, United States of America, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Rheumatology, Cleveland, United States of America, University of Utah School of Medicine and Salt Lake City Veterans Affairs Medical Center, Rheumatology, Salt Lake City, United States of America, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Rheumatology, Seattle, United States of America,
Abstract
ASSESSMENT OF PAIN OUTCOMES IN A PHASE 2 TRIAL OF DEUCRAVACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITISOrg: Bristol Myers Squibb, Stanford University School of Medicine, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Rheumatology, Seattle, United States of America, University of Washington School of Medicine, Institute of Medical Science, University of Toronta,
Abstract
ASSOCIATIONS BETWEEN CLINICAL CHARACTERISTICS AND SCREENING MRI FINDINGS: EXPLORATORY ANALYSIS OF THE ONGOING PHASE 4, MULTICENTER, RANDOMIZED, CONTROLLED STAR STUDY OF BIOLOGIC-NAÏVE PATIENTS WITH PsA WITH MRI-CONFIRMED AXIAL INVOLVEMENTOrg: Janssen Scientific Affairs, Drexel University College of Medicine, Janssen Research & Development, Clario, Amsterdam University Medical Center, Vrije Universiteit Amsterdam,
Abstract
BASELINE BIOMARKERS PREDICT BETTER RESPONSES TO DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITISOrg: Bristol Myers Squibb, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Rheumatology, Seattle, United States of America, Medical University of Vienna, University of Rochester Medical Center, University of Toronto,